Approved medicines Human trials in product label Metabolic health
Also discussed as: Trulicity
What it is and how it works
Dulaglutide contains modified GLP-1 components linked to an immunoglobulin fragment. It activates GLP-1 receptors and supports glucose-dependent insulin secretion. This engineered structure explains why a broad peptide library can include medicines more complex than a short amino-acid chain.
Source for the mechanism context →A closer look at the cited evidence
Human trials in product label
This label describes the selected source below. It is not a complete ranking of the literature, a safety score, or an approval status.
- Study or assessment
- DailyMed — Trulicity mechanism and clinical studies
- Design
- Label summaries of glucose-control trials and a cardiovascular-outcomes study.
- Who or what was studied
- Defined type 2 diabetes populations; eligibility differs by study.
- What was observed
- The evidence supports specific labeled glucose-control and cardiovascular-risk-reduction uses.
- Limits of interpretation
- Results do not establish universal cardiovascular prevention or a weight-management indication for everyone.
What the evidence means
Clinical studies in the label address glucose control and cardiovascular outcomes in defined diabetes populations.
Approval and regulatory context
Trulicity has FDA-approved diabetes and specific cardiovascular-risk-reduction indications. It is not interchangeable with every GLP-1 product.
Safety and uncertainty
The label includes a thyroid C-cell tumor boxed warning and gastrointestinal and pancreatic precautions.
What remains uncertain
A finding in people with type 2 diabetes cannot automatically answer a question about people without diabetes. Different GLP-1 medicines also have different structures, indications, and evidence.
These summaries are introductory and are not a complete account of the literature, adverse effects, contraindications, or interactions. Absence of a listed risk does not mean absence of risk. Different compounds, formulations, and routes cannot be treated as interchangeable.
Sources behind this overview
Read the source in its full context. Source links support the overview; they do not imply endorsement of this library by the source organization.